Abstract 5031
Background
The outcome of high risk stage III melanoma patients (pts) is poor, with a 5-year overall survival (OS) rate of < 50%. Adjuvant (adj) high dose IPI , adj NIVO and pembrolizumab improved RFS. Neo-adjuvant (neoadj) treatment may be an even more favorable approach as immune checkpoint inhibition is of greatest value at the moment of TCR triggering and therefore dependent on the amount of antigen present. In our previous phase Ib OpACIN study the pathological RR (pRR) was 78% in the neoadj arm, and to date after 25 months of median follow-up none of the responders has relapsed. This raises the question whether such pts need to undergo complete lymph node dissection (CLND). A prerequisite for such an approach would be an analysis method that reliably indicates pathological response within the whole lymph node bed, without the need for CLND.
Methods
To address this question an in-house developed magnetic marker was placed ultrasound-guided at baseline into the largest regional lymph node metastasis of pts participating in OpACIN-neo, (NCT02977052), a phase 2 trial aiming at identification of the optimal neoadj combination scheme of IPI and NIVO in stage IIIB/C melanoma pts followed by CLND.
Results
So far, 11 pts participated in this side trial of OpACIN-neo. No complications from marker placing were observed, and all magnetic markers were retrieved during the CLND after 6 weeks of neoadj IPI+NIVO. 10/11 marked lymph-nodes (LN were representative in their response for the whole CLND specimen, i.e. index node showed a complete or partial response (PR), all others on CLND showed the same or better responses. Only 1 case was incongruent, as the index LN had 60% vital tumor (no response) compared to another LN (40% vital tumor, PR).
Conclusions
Our early exploratory data from this pilot study indicate that marked LN in stage III melanoma could serve as response indicators for the outcome of the whole CLND after neoadj IPI+NIVO. If confirmed, our data can open the path towards response-driven extent of lymph-node dissection in macroscopic stage III melanoma.
Clinical trial identification
NCT02977052.
Legal entity responsible for the study
Alexander C.J. van Akkooi.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
A.C.J. van Akkooi: Consulting or advisory: Amgen, Novartis, MSD Oncology, Merck; Travel, accommodations, expenses: Amgen, Roche, Novartis; Research funding: Amgen, Novartis. C.U. Blank: Personal fees, Advisory role: MSD, BMS, Roche, GSK, Novartis, Pfizer, Lilly; Grants: BMS, Novartis, outside the submitted work. All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract